Yee David S, Narula Navneet, Ramzy Ibrahim, Boker John, Ahlering Thomas E, Skarecky Douglas W, Ornstein David K
Department of Urology, University of California Irvine Medical Center, Orange, CA 92868, USA.
Arch Pathol Lab Med. 2007 Jun;131(6):902-8. doi: 10.5858/2007-131-902-RAIPEI.
Annexin II is a calcium-dependent phospholipid-binding protein that plays a role in many cellular functions, including apoptosis, signal transduction, and cellular motility. The protein is strongly expressed in normal prostatic epithelial glands, but its expression in benign prostatic lesions has not been reported. Although commonly underexpressed in prostate cancer, the association of reduced expression with pathologic grade and stage is unknown.
To compare annexin II expression in benign prostatic lesions with expression in high-grade prostatic intraepithelial neoplasia and prostate cancer, as well as to correlate expression levels with pathologic grade and stage.
A semi-quantitative assessment of annexin II expression was performed in radical prostatectomy specimens from 74 patients and prostate needle core biopsy specimens from 13 patients. Foci with normal prostatic glands, atrophic glands, basal cell hyperplasia, high-grade prostatic intraepithelial neoplasia, and prostatic adenocarcinoma were evaluated.
Annexin II expression was present in more than 50% of glands in most (>85%) samples of benign prostatic epithelium, atrophic glands, and basal cell hyperplasia. In high-grade prostatic intraepithelial neoplasia, annexin II staining was markedly reduced in epithelial cells but not in basal cells. Annexin II was absent or focally present in moderately differentiated adenocarcinoma but was retained in poorly differentiated adenocarcinomas.
Reduced annexin II expression may be a useful diagnostic biomarker to help identify small foci of moderately differentiated adenocarcinoma on needle core biopsy specimens since it is consistently expressed in benign prostatic glands. Re-expression of annexin II in poorly differentiated adenocarcinoma may provide prognostic information.
膜联蛋白II是一种钙依赖性磷脂结合蛋白，在许多细胞功能中发挥作用，包括细胞凋亡、信号转导和细胞运动。该蛋白在正常前列腺上皮腺中强烈表达，但在良性前列腺病变中的表达尚未见报道。虽然在前列腺癌中通常表达不足，但表达降低与病理分级和分期的关系尚不清楚。
比较良性前列腺病变中膜联蛋白II的表达与高级别前列腺上皮内瘤变和前列腺癌中的表达，并将表达水平与病理分级和分期相关联。
对74例患者根治性前列腺切除术标本和13例患者前列腺穿刺活检标本进行膜联蛋白II表达的半定量评估。对具有正常前列腺腺、萎缩腺、基底细胞增生、高级别前列腺上皮内瘤变和前列腺腺癌的病灶进行评估。
在大多数（>85%）良性前列腺上皮、萎缩腺和基底细胞增生样本中，超过50%的腺中存在膜联蛋白II表达。在高级别前列腺上皮内瘤变中，上皮细胞中膜联蛋白II染色明显减少，但基底细胞中未减少。膜联蛋白II在中分化腺癌中缺失或局灶性存在，但在低分化腺癌中保留。
膜联蛋白II表达降低可能是一种有用的诊断生物标志物，有助于在穿刺活检标本上识别中分化腺癌的小病灶，因为它在良性前列腺腺中持续表达。膜联蛋白II在低分化腺癌中的重新表达可能提供预后信息。
